fbpx

COVID Long Hauler

Earn up to 499 Mobile Care Rewards.From: $379.00 / week for 3 weeks

Our COVID Long Hauler treatment protocol one is focused on macrophage/monocyte repolarization and mast cell stabilization. This is combined with powerful anti-inflammatory drugs and reduction in oxidative stress. Protocol two uses NAD+ and liposomal supplements to reduce chronic inflammation and oxidative stress. If you have tested positive for COVID in the past and are experiencing symptoms, months after your positive test and or hospitalization, please contact us for a free consult. For more information on each protocol scroll on down!

  • General COVID
  • Pulmonary COVID
  • Inflammatory & Muskeloskelatal COVID 
  • IV Protocol
Clear

The Long Haul COVID-19 Syndrome (LHCS or Long Hauler) is an often debilitating syndrome characterized by a multitude of symptoms such as prolonged malaise, headaches, generalized fatigue, sleep difficulties, smell disorder, decreased appetite, painful joints, dyspnea, chest pain and cognitive dysfunction. The incidence of symptoms after COVID-19 varies from as low as 10% to as high as 80%. LHCS is not only seen after the COVID-19 infection but it is being observed in some people that have received vaccines (likely due to monocyte activation by the spike protein from the vaccine). A puzzling feature of the LHCS syndrome is that it is not predicted by initial disease severity; post-COVID-19 frequently affects mild-to-moderate cases and younger adults that did not require respiratory support or intensive care.

The symptom set of LHCS in the majority of cases is very similar to the chronic inflammatory response syndrome (CIRS)/myalgic encephalomyelitis/chronic fatigue syndrome, although in LHCS, symptoms tend to improve slowly in the majority of the cases. Furthermore, the similarity between the mast cell activation syndrome and LHCS has been observed, and many consider post-COVID-19 to be a variant of the mast cell activation syndrome. LHCS is highly heterogenous and likely results from a variety of pathogenetic mechanisms. Furthermore, it is likely that delayed treatment (with ivermectin) in the early symptomatic phase will result in a high viral load, which increases the risk and severity of LHCS.

If you have tested positive for COVID in the past and are experiencing symptoms, months after your positive test and or hospitalization, please contact us for a free consult.

General COVID

  • NAD+ 100mg subcutaneous x 20 days; followed by
  • Synanpsin RG3 Nasal Spray x60 days
  • Methylene Blue /Ascorbic Acid 4/75mg Capsules x 6 months
  • Montelukast 10mg
  • Low-Dose Naltrexone (LDN) x 6 months
  • Co-Enzyme Q10 Intramuscular Injections x 10 weeks
  • D3 Intramuscular Injections x 6 months

Inflammatory & Muskeloskelatal COVID 

  • NAD+ 100mg subcutaneous x 20 days; followed by
  • Synanpsin RG3 Nasal Spray x60 days
  • Pentosan Polysulfate  x 6 weeks
  • Methylene Blue /Ascorbic Acid 4/75mg Capsules x 6 months
  • ARA 290 daily x 30 days every 3 months (2 months total ARA 290).
  • Low-Dose Naltrexone (LDN) x 6 months
  • Co-Enzyme Q10 Intramuscular Injections x 10 weeks
  • D3 Intramuscular Injections x 6 months

IV Protocol (Denver Metro Only)

  • Weekly infusion x 3 Weeks of:
    • Glutathione 2 Grams in 100ml saline (High-Dose)
    • 1000ml of saline with:
      • Vitamin C 10 Grams (High-Dose)
      • NAD+ 250mg
      • B12 2.5mg
      • B-Complex
      • Amino Acids
      • Copper/Zinc/Selenium/Manganese

 

Limited data is available on LHCS and current treatment is focused on symptoms with multiple different medications and supplements. There is no guarantee that the treatment offered by Mobile Care or any provider will reduce or cure LHCS. Please call or book a free consult online.

Protocol

General COVID, Inflammatory & Musculoskeletal COVID , IV Protocol

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Mobile Care Rewards